enGene Therapeutics (ENGN) Interest Coverage Ratio (2023 - 2026)
enGene Therapeutics (ENGN) posted quarterly Interest Coverage Ratio of 2.94 for Q2 2026, up 51.48% year-over-year from 1.94 in Q2 2025, and up 93.09% quarter-over-quarter from 42.6 in Q1 2026.
enGene Therapeutics (ENGN) Interest Coverage Ratio (2023 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Interest Coverage Ratio for 4 consecutive years, with 2.94 the latest figure, recorded in Q2 2026.
- In Q2 2026, Interest Coverage Ratio rose 51.48% year-over-year to 2.94; the TTM figure through Apr 2026 stood at 12.2 (up 37.94% YoY), while the FY2025 annual figure was 11.22, down 782.23% from the prior year.
- Interest Coverage Ratio advanced to 2.94 in Q2 2026 per ENGN's latest filing, from 42.6 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 5221.0 in Q4 2023 and bottomed at 110.47 in Q4 2024.
- Historically, Interest Coverage Ratio has averaged 354.22 across 4 years, with a median of 5.2 in 2023.
- Annual changes were most pronounced in 2024 — Interest Coverage Ratio soared 89.56% — and 2025, when it slumped 1342.63%.
- enGene Therapeutics' Interest Coverage Ratio stood at 5221.0 in 2023, then tumbled by 102.12% to 110.47 in 2024, then soared by 74.76% to 27.88 in 2025, then soared by 89.45% to 2.94 in 2026.
- Business Quant data shows ENGN's Interest Coverage Ratio at 2.94 in Q2 2026, 42.6 in Q1 2026, and 27.88 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.41 Bn | 130.56 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.41 Bn | 59.23 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.56 Bn | 52.43 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.06 Bn | 36.96 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 30.95 Bn | 27.65 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 27.48 Bn | 9.09 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.31 Bn | 26.15 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.04 Bn | 26.20 Bn | - | 1.42 |
| 10 | enGene Therapeutics | 125.50 Mn | 125.50 Mn | - | -42.91 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -2.94 |
| Jan 31, 2026 | -42.60 |
| Oct 31, 2025 | -27.88 |
| Jul 31, 2025 | -7.25 |
| Apr 30, 2025 | -6.06 |
| Jan 31, 2025 | -33.27 |
| Oct 31, 2024 | -110.47 |
| Jul 31, 2024 | -0.81 |
| Apr 30, 2024 | -0.42 |
| Jan 31, 2024 | -17.96 |
| Oct 31, 2023 | 5,221.00 |
| Jul 31, 2023 | -4.33 |
| Apr 30, 2023 | -4.02 |
| Jan 31, 2023 | -3.94 |